Literature DB >> 9722204

Early liver dysfunction in schistosomiasis.

L Camacho-Lobato1, D R Borges.   

Abstract

BACKGROUND/AIMS: Liver dysfunction is said to occur only late in the course of schistosomiasis. As albumin levels tend to be normal, the observed prolonged prothrombin time is thought to arise from subclinical consumption coagulopathy. The aim of this study was to further evaluate this matter by studying the role of Schistosoma mansoni and liver function in the genesis of the compromised haemostasis tests in chronic "pure" schistosomiasis patients.
METHODS: Twenty-five adults with chronic "pure" schistosomiasis were selected: 12 with the hepatointestinal form (group 2) and 13 with the compensated hepatosplenic form (group 3), as well as 10 matched control individuals (group 1). Alcoholism, viral hepatitis B and C, malnutrition (BMI<20 kg/m2), use of anticoagulant or anti-aggregant drugs and chronic diseases apart from schistosomiasis were carefully excluded. All patients were submitted to abdominal ultrasound and upper digestive endoscopy. Blood samples were used for routine hepatic tests and for transthyretin, prothrombin, antithrombin and protein C antigen determinations by immunodiffusion. Laboratory markers of coagulation activation (prothrombin fragment1+2(F1+2), serine esterases-antithrombin complexes (ATM) and plasminogen activator, tissue type activity (t-PA) were also assayed by ELISA and photometric determination, respectively.
RESULTS: Decreased plasma levels of transthyretin (p<0.001), protein C (p:0.006), prothrombin (p:0.022) and antithrombin (p:0.008) contrasted with normal albuminaemia (p:0.094), F1+2 (p:0.061) and ATM (p:0.714) plasma levels in group 3 patients; t-PA activity (p:0.001) on the other hand, were increased in this group.
CONCLUSIONS: These results suggest impairment of liver clearance and protein synthesis capacity rather than consumption coagulopathy. They also indicate that changes in liver function are not a late event in the course of schistosomiasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9722204     DOI: 10.1016/s0168-8278(98)80008-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

1.  Thrombocytemia as a predictor of portal hypertension in schistosomiasis.

Authors:  M R Souza; C F Toledo; D R Borges
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

2.  Gamma-glutamyltransferase decreases in patients with the chronic form of schistosomiasis mansoni treated with ursodeoxycholic acid.

Authors:  P de J Ribeiro; J L Narciso; C F de Toledo; D R Borges
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

3.  A Comparative Cross-Sectional Study of Coagulation Profiles and Platelet Parameters of Schistosoma mansoni-Infected Adults at Haik Primary Hospital, Northeast Ethiopia.

Authors:  Habtye Bisetegn; Daniel Getacher Feleke; Hussen Ebrahim; Melkam Tesfaye; Alemu Gedefie; Yonas Erkihun
Journal:  Interdiscip Perspect Infect Dis       Date:  2022-06-27

4.  Endothelial markers in schistosomiasis patients with or without portal hypertension.

Authors:  Carlos Fischer de Toledo; Claudia Teresa Carvente; David Carlos Shigueoka; Durval Rosa Borges
Journal:  Dig Dis Sci       Date:  2008-08-27       Impact factor: 3.199

5.  Relationship between splenomegaly and hematologic findings in patients with hepatosplenic schistosomiasis.

Authors:  Luiz Arthur Calheiros Leite; Ana Lúcia Coutinho Domingues; Edmundo Pessoa Lopes; Rita de Cássia Dos Santos Ferreira; Adenor de Almeida Pimenta; Caíque Silveira Martins da Fonseca; Bianka Santana Dos Santos; Vera Lúcia de Menezes Lima
Journal:  Rev Bras Hematol Hemoter       Date:  2013

6.  MAPKAP1 rs10118570 polymorphism is associated with anti-infection and anti-hepatic fibrogenesis in schistosomiasis japonica.

Authors:  Xiao Zhu; Jinfang Zhang; Wenguo Fan; Yunguo Gong; Jianhua Yan; Zhidong Yuan; Lang Wu; Hongjing Cui; Haiqing Luo; Qingming Kong; Li Tang; Shuilong Leng; Yufeng Liao; Weiming Fu; Qin Xiao; Dongpei Li
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

7.  Increased hepatotoxicity among HIV-infected adults co-infected with Schistosoma mansoni in Tanzania: A cross-sectional study.

Authors:  Amon I Marti; Soledad Colombe; Peter J Masikini; Samuel E Kalluvya; Luke R Smart; Bahati M Wajanga; Hyasinta Jaka; Robert N Peck; Jennifer A Downs
Journal:  PLoS Negl Trop Dis       Date:  2017-08-17

8.  Hematological and Biochemical Profile of Patients Infected with Schistosoma mansoni in Comparison with Apparently Healthy Individuals at Sanja Town, Northwest Ethiopia: A Cross-Sectional Study.

Authors:  Nega Dessie; Wossenseged Lema; Mulugeta Aemero
Journal:  J Trop Med       Date:  2020-05-06

9.  Splenectomy Improves Hemostatic and Liver Functions in Hepatosplenic Schistosomiasis Mansoni.

Authors:  Luiz Arthur Calheiros Leite; Adenor Almeida Pimenta Filho; Rita de Cássia dos Santos Ferreira; Caíque Silveira Martins da Fonseca; Bianka Santana dos Santos; Silvia Maria Lucena Montenegro; Edmundo Pessoa de Almeida Lopes; Ana Lúcia Coutinho Domingues; James Stuart Owen; Vera Lucia de Menezes Lima
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

10.  Hemostatic dysfunction is increased in patients with hepatosplenic schistosomiasis mansoni and advanced periportal fibrosis.

Authors:  Luiz Arthur Calheiros Leite; Adenor Almeida Pimenta Filho; Caíque Silveira Martins da Fonseca; Bianka Santana dos Santos; Rita de Cássia dos Santos Ferreira; Silvia Maria Lucena Montenegro; Edmundo Pessoa Lopes; Ana Lúcia Coutinho Domingues; James Stuart Owen; Vera Lúcia de Menezes Lima
Journal:  PLoS Negl Trop Dis       Date:  2013-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.